Understanding the pathophysiology of typical acute respiratory distress syndrome and severe COVID-19

Simple item page
dc.contributor.authorLorenzo Ball
dc.contributor.authorPedro Leme Silva
dc.contributor.authorDaniele Roberto Giacobbe
dc.contributor.authorMatteo Bassetti
dc.contributor.authorGustavo Zubieta‐Calleja
dc.contributor.authorPatrícia R. M. Rocco
dc.contributor.authorPaolo Pelosi
dc.coverage.spatialBolivia
dc.date.accessioned2026-03-22T21:02:38Z
dc.date.available2026-03-22T21:02:38Z
dc.date.issued2022
dc.descriptionCitaciones: 34
dc.description.abstractARDS is defined as a syndrome rather than a distinct pathologic entity. There is great heterogeneity regarding the pathophysiologic, clinical, radiologic, and biological phenotypes in patients with ARDS, challenging clinicians, and scientists to discover new therapies. COVID-19 has been described as a cause of pulmonary ARDS and has reopened many questions regarding the pathophysiology of ARDS itself. COVID-19 lung injury involves direct viral epithelial cell damage and thrombotic and inflammatory reactions. There are some differences between ARDS and COVID-19 lung injury in aspects of aeration distribution, perfusion, and pulmonary vascular responses.
dc.identifier.doi10.1080/17476348.2022.2057300
dc.identifier.urihttps://doi.org/10.1080/17476348.2022.2057300
dc.identifier.urihttps://andeanlibrary.org/handle/123456789/85592
dc.language.isoen
dc.publisherTaylor & Francis
dc.relation.ispartofExpert Review of Respiratory Medicine
dc.sourceUniversity of Genoa
dc.subjectARDS
dc.subjectMedicine
dc.subjectPathophysiology
dc.subjectPneumonia
dc.subjectIntensive care medicine
dc.subjectDiffuse alveolar damage
dc.subjectCoronavirus disease 2019 (COVID-19)
dc.subjectRespiratory failure
dc.subjectViral pneumonia
dc.subjectCoronavirus
dc.titleUnderstanding the pathophysiology of typical acute respiratory distress syndrome and severe COVID-19
dc.typereview

Files

Collections

Artículo Científico Publicado